Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2000;18(12):2413–2418.
DOI: 10.1200/JCO.2000.18.12.2413
Gilligan TD, Einhorn LH, Houlihan MJ, et al. Management of relapsed and refractory germ cell tumors: Recommendations of a consensus panel. J Clin Oncol. 2017;35(15):2142–2153.
Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357(4):340–348.
DOI: 10.1056/NEJMoa067749
Heidenreich A, Fizazi K; ESMO Guidelines Committee. Testicular cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(11):1352–1363.
Lorch A, Beyer J, Bascoul-Mollevi C, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28(33):4906–4911.
DOI: 10.1200/JCO.2009.26.8128
Harstrick A, Schmoll HJ, Nitz AJ, et al. Cisplatin–ifosfamide salvage therapy in refractory or relapsing germ cell carcinoma: A multicenter retrospective study. J Clin Oncol. 1991;9(8):1549–1555.
DOI: 10.1200/JCO.1991.9.9.1549
Pizzocaro G, Salvioni R, Piva L, et al. Modified cisplatin, etoposide (or vinblastine), and ifosfamide salvage therapy for male germ-cell tumors: Long-term results. Ann Oncol. 1992;3(3):211–216.
DOI: 10.1093/oxfordjournals.annonc.a058154
Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23(27):6549–6555.
DOI: 10.1200/JCO.2005.19.638
Fizazi K, Gravis G, Flechon A, et al. Gemcitabine, ifosfamide, and cisplatin salvage therapy for relapsed metastatic germ cell tumors: Results of GETUG 13 phase II trial. Ann Oncol. 2014;25(5):987–991.
DOI: 10.1093/annonc/mdu099
McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol. 1997;15(7):2559–2563.
DOI: 10.1200/JCO.1997.15.7.2559
Gilligan TD, Houlihan MJ, Einhorn LH, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16(7):2500–2504.
DOI: 10.1200/JCO.1998.16.7.2500
Motzer RJ, Baird GS, Jonasch E, et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol. 1996;14(3):1098–1105.
DOI: 10.1200/JCO.1996.14.4.1098
Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin refractory germ cell tumors: A phase II study. Ann Oncol. 2004;15(3):493–497.
DOI: 10.1093/annonc/mdh103
Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: Evidence from a large international database. J Clin Oncol. 2011;29(16):2178–2184.
DOI: 10.1200/JCO.2010.32.6678
Seidel C, Kollmannsberger C, Bamberg M, et al. Outcomes of early versus late administration of high-dose chemotherapy in relapsed germ cell tumors: A multicenter retrospective analysis. Br J Cancer. 2024;130(3):389–397.
Schmoll HJ, Kollmannsberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 2003;21(21):4083–4091.
DOI: 10.1200/JCO.2003.09.035
Pico JL, Rosti G, Kramar A, et al. A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors: The IT94 study. Ann Oncol. 2005;16(7):1152–1159.
DOI: 10.1093/annonc/mdi228
Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011 Jun 1;29(16):2178-84.
DOI: 10.1200/JCO.2010.32.6678
González-Billalabeitia E, Sepúlveda JM, Maroto P. et al; Spanish Germ Cell Cancer Group and the Spanish Oncology Genitourinary Group. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. Eur Urol Focus. 2017 Apr;3(2-3):280-286.
DOI: 10.1016/j.euf.2016.07.002
Gillessen S, Collette L, Collette C, et al. Results of a phase III randomized study comparing sequential high-dose chemotherapy versus a single high-dose chemotherapy after conventional dose chemotherapy for relapsed germ cell tumors. Eur Urol. 2013;63(4):651–660.
Lorch A, Beyer J, Bascoul-Mollevi C, et al. High-dose chemotherapy as second salvage treatment for recurrent germ cell tumors: Results from a large international database. J Clin Oncol. 2012;30(15):1826–1833.
Moore KA, Connell CM, Ritchie AW, et al. Low-dose oral etoposide for the treatment of refractory germ cell tumors: A single-institution experience. Br J Cancer. 2001;85(4):606–610.
Desai NB, Wen S, Einhorn LH, et al. Role of adjuvant radiotherapy after chemotherapy in salvage management of seminoma: A retrospective study. Int J Radiat Oncol Biol Phys. 2008;72(2):365–372.
Loehrer PJ, Gonin R, Nichols CR, et al. Pulmonary metastasectomy in relapsed seminoma: A retrospective analysis from the Indiana University experience. J Urol. 2000;163(4):1186–1189.
Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: Diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998;159(1):133–138.
DOI: 10.1016/S0022-5347(01)64035-7
Gilligan TD, Papadopoulos NE, Schweber R, et al. Targeted therapies in refractory germ cell tumors: A phase II study of sunitinib. Urology. 2015;85(3):652.e1–652.e7.
van Groningen AA, de Wit R, Meuleman EJ, et al. Phase II study of olaparib in germ cell tumors with homologous recombination deficiency. Eur Urol. 2022;82(5):516–523.
Link M, Mara ML, Moran M, et al. Preclinical development of CLDN6-targeted CAR T cells for germ cell tumors. Mol Ther Oncolytics. 2024;25:66–75.
Powles T, Shamash J, Aggarwal R, et al. Pembrolizumab for platinum-refractory germ cell tumors: A phase II study. Ann Oncol. 2018;29(6):1486–1490.
Logan TF, Lara PN Jr, Gumerlock PH, et al. Phase II trial of brentuximab-vedotin in CD30-positive refractory germ cell tumors. Oncologist. 2018;23(7):698–704.
Gilligan TD, Tobias JS, Hanna NH, et al. Current challenges and future directions in the treatment of cisplatin-resistant germ cell tumors. Clin Cancer Res. 2023;29(12):2517–2528.
Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med. 1988 Oct 1;109(7):540–6.
DOI: 10.7326/0003-4819-109-7-540
Mead GM, Cullen MH, Huddart R, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second line (post BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a Medical Research Council trial. Br J Cancer. 2005 Jul 25;93(2):178–184.
DOI: 10.1038/sj.bjc.6602682
Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high dose chemotherapy with tandem transplant. J Clin Oncol. 2007 Feb 10;25(5):513–6.
DOI: 10.1200/JCO.2006.07.7271
Kollmannsberger C, Hartmann JT, Kanz L, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2004 Jan 1;22(1):108–114.
DOI: 10.1200/JCO.2004.06.068
Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin refractory or multiply relapsed germ cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol. 2008 Mar;19(3):448–453.
DOI: 10.1093/annonc/mdm526
Feldman DR, Patil S, Trinos MJ, et al. Progression free and overall survival in patients with relapsed/refractory germ cell tumors treated with single agent chemotherapy: endpoints for clinical trial design. Cancer. 2012 Feb 15;118(4):981 6.
DOI: 10.1002/cncr.26375
Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol. 1990 Feb;17(1):36–39.
Bhatia S, Abonour R, Porcu P, et al. High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol. 2000 Oct 1;18(19):3346–51.
DOI: 10.1200/JCO.2000.18.19.3346
Kondagunta GV, Bacik J, Sheinfeld, et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2007 Jan 1;25(1):85–90.
DOI: 10.1200/JCO.2006.06.9401
Feldman DR, Sheinfeld J, Bajorin DF, et al. TI CE high dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010 Apr 1;28(10):1706–1713.
DOI: 10.1200/JCO.2009.25.1561
Rick O, Beyer J, Kingreen D, et al. High dose chemotherapy in germ cell tumours: a large single centre experience. Eur J Cancer. 1998 Nov;34(12):1883–1888.
DOI: 10.1016/S0959-8049(98)00272-X
Rick O, Bokemeyer C, Beyer J, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high dose carboplatin, etoposide, and thiotepa followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 2001 Jan 1;19(1):81–88.
DOI: 10.1200/JCO.2001.19.1.81
Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IGH, Berdel WE, et al. Single Versus Sequential High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: A Prospective Randomized Multicenter Trial of the German Testicular Cancer Study Group. Journal of Clinical Oncology 2007;25:2778–84.
DOI: 10.1200/JCO.2006.09.2148
Lorch A, Kleinhans A, Kramar A, Kollmannsberger CK, Hartmann JT, Bokemeyer C, et al. Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial. Journal of Clinical Oncology 2012;30:800–5.
DOI: 10.1200/JCO.2011.38.6391
Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, et al. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989;7:932–9.
DOI: 10.1200/JCO.1989.7.7.932
Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994;12:1223–31.
DOI: 10.1200/JCO.1994.12.6.1223
Lorch A, Neubauer A, Hackenthal M, Dieing A, Hartmann JT, Rick O, et al. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Annals of Oncology 2010;21:820–5.
DOI: 10.1093/annonc/mdp366
Número de descargas:
947
Número de visitas:
59
Citas:
0
